• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Vivesto

9.18 SEK

0.00 %

Less than 1K followers

VIVE

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
0.00 %
+10.07 %
+14.75 %
-21.87 %
-20.58 %
-54.64 %
-65.31 %
-96.59 %
-99.42 %

Vivesto is a pharmaceutical company focused on developing innovative treatments for serious oncology diseases. The company is researching new therapies that can improve patient outcomes and quality of life. The company operates globally with a primary presence in Europe and North America. Vivesto was founded in 1988 and is headquartered in Uppsala, Sweden.

Read more
Market cap
101.64M SEK
Turnover
158.49K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
13.8.
2026

Interim report Q2'26

12.11.
2026

Interim report Q3'26

11.2.
2027

Annual report '26

Regulatory press release6/5/2026, 6:00 AM

Vivesto appoints Björn Svanström as CFO

Vivesto
Regulatory press release5/29/2026, 6:00 AM

New number of shares and votes in Vivesto

Vivesto
Press release5/26/2026, 4:30 AM

DNB Carnegie Access: Vivesto: Minor model adjustments

Vivesto

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release5/13/2026, 11:00 AM

Vivesto announces timetable for reverse share split

Vivesto
Press release5/7/2026, 5:48 PM

DNB Carnegie Access: Vivesto: Purring along – Q1 review

Vivesto
Regulatory press release5/7/2026, 8:21 AM

Report from Annual General Meeting in Vivesto AB

Vivesto
Regulatory press release4/1/2026, 6:05 AM

Notice of Annual General Meeting in Vivesto AB

Vivesto
Regulatory press release4/1/2026, 6:00 AM

The Board of Directors of Vivesto proposes a reverse share split and reduction of the share capital

Vivesto
Press release3/13/2026, 7:00 AM

First dogs dosed in Vivesto's PK/toxicology study with Cantrixil

Vivesto
Press release3/2/2026, 6:08 AM

DNB Carnegie Access: Vivesto: Several inflection points approaching – Q4 review

Vivesto
Regulatory press release2/27/2026, 7:30 AM

New number of shares and votes in Vivesto

Vivesto
Regulatory press release1/29/2026, 8:40 PM

Vivesto carries out a directed share issue to guarantors in connection with the completed rights issue

Vivesto
Regulatory press release1/23/2026, 4:45 PM

Vivesto announces outcome of the rights issue

Vivesto
Press release1/12/2026, 3:40 PM

DNB Carnegie Access: Vivesto: Intervju - Händelserikt år står för dörren

Vivesto
Regulatory press release1/2/2026, 1:30 PM

Vivesto publishes information document regarding the rights issue

Vivesto
Regulatory press release12/22/2025, 9:30 AM

Report from Extraordinary General Meeting in Vivesto AB

Vivesto
Press release12/16/2025, 7:00 AM

Vivesto signs Liberi Group to accelerate partnering activities for Paccal Vet and Cantrixil programs

Vivesto
Press release11/24/2025, 7:00 AM

Vivesto holds a live-streamed business update today November 24

Vivesto
Press release11/21/2025, 6:40 AM

DNB Carnegie Access: Vivesto: Raising capital – Q3 review

Vivesto
Press release11/20/2025, 10:15 AM

DNB Carnegie Access: Vivesto - Q3 25 - Rapportintervju

Vivesto